Blueprint Medicines Co. (NASDAQ:BPMC) is DAFNA Capital Management LLC's 10th Largest Position

DAFNA Capital Management LLC lifted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 23.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,763 shares of the biotechnology company's stock after buying an additional 28,000 shares during the period. Blueprint Medicines makes up approximately 3.3% of DAFNA Capital Management LLC's investment portfolio, making the stock its 10th biggest holding. DAFNA Capital Management LLC owned 0.24% of Blueprint Medicines worth $13,062,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Cerity Partners LLC acquired a new stake in Blueprint Medicines during the 4th quarter worth about $291,000. Empirical Asset Management LLC purchased a new position in Blueprint Medicines during the fourth quarter valued at approximately $2,348,000. Stephens Inc. AR acquired a new position in Blueprint Medicines in the fourth quarter valued at approximately $321,000. Bank of New York Mellon Corp boosted its position in Blueprint Medicines by 2.4% in the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock worth $26,465,000 after purchasing an additional 7,101 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of Blueprint Medicines by 63.9% during the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 1,023 shares during the period.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, May 2nd. JMP Securities restated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. StockNews.com raised Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an "outperform" rating on the stock. Finally, Piper Sandler upped their target price on Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines presently has an average rating of "Moderate Buy" and an average target price of $126.56.

Insider Activity

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares of the company's stock, valued at $1,692,167.40. The trade was a 14.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. This represents a 3.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,503 shares of company stock valued at $1,027,931 in the last quarter. Insiders own 4.21% of the company's stock.

Blueprint Medicines Trading Down 1.0 %

Shares of BPMC traded down $1.02 during midday trading on Friday, reaching $97.74. The company had a trading volume of 621,844 shares, compared to its average volume of 780,742. The firm has a 50 day simple moving average of $88.49 and a 200-day simple moving average of $93.81. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a market cap of $6.31 billion, a PE ratio of -90.50 and a beta of 0.83. Blueprint Medicines Co. has a 1-year low of $73.04 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The firm had revenue of $149.41 million during the quarter, compared to analysts' expectations of $158.31 million. During the same period last year, the company earned $1.40 EPS. The business's quarterly revenue was up 55.5% on a year-over-year basis. Research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.